ReviewRheumatology and therapy2024
Epidemiology of Sjögren's: A Systematic Literature Review.
Review in Rheumatology and therapy, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed.
- Systematic review of the efficacy of rituximab in the management of central nervous system involvement among adults with Sjögren's disease.BMC rheumatology · 2026Article
- Imaging correlates of disease activity and patient-reported symptoms in primary Sjögren's disease: an ultrasonographic and scintigraphic study.Rheumatology international · 2026Article
- Beyond Dryness: Mapping the Psychological and Cognitive Burden in Sjögren's Disease-A Narrative Review.Journal of clinical medicine · 2026Review
- The SjD Map: an interactive pathway tour into Sjögren's disease signalling mechanisms.NPJ systems biology and applications · 2026Article
- Oral health-related quality of life in Sjögren disease and non-Sjögren sicca: a cross-sectional study.Journal of patient-reported outcomes · 2026Article
- Comparative Analysis of Clinical Trials of Biologic Drugs for Patients with Primary Sjögren's Syndrome.Journal of clinical medicine · 2026Review
- Spotlight on Sjögren's: a patient perspective on burden of illness and unmet needs - results from a real-world survey.RMD open · 2026Article
- Variants inInternational journal of molecular sciences · 2026Article
- Nanotechnology-Based Modulation of Autoimmune Microenvironments in Sjögren's Syndrome: A Review of Mechanistic Perspectives.International journal of nanomedicine · 2026Review
- Transcriptomic changes in the lacrimal glands of a Sjogren's disease animal model highlight key molecular mediators and altered biological functions underpinning glandular inflammation and hypofunction.Frontiers in ophthalmology · 2026Article
- TLR7 and TLR9 have overlapping but distinct roles in systemic lupus erythematosus and Sjögren's disease.Frontiers in immunology · 2026Review
- Article
- Sjögren's Hands-On Practice Exchange (SHAPE): a qualitative, expert opinion project in Sjögren's disease clinical practice.BMC rheumatology · 2025Article
- Sjogren's syndrome-Case series and literature review.Journal of oral and maxillofacial pathology : JOMFP · 2025Article
- Article
- A Review of the Current Clinical Aspects of Sjögren's Disease: Geographical Difference, Classification/Diagnostic Criteria, Recent Advancements in Diagnostic Methods, and Molecular Targeted Therapy.Journal of clinical medicine · 2025Review
- Cross-Population Analysis of Sjögren's Syndrome Polygenic Risk Scores and Disease Prevalence: A Pilot Study.Genes · 2025Article
- Insights into Patient Heterogeneity in Sjögren's Disease.International journal of molecular sciences · 2025Review
- B lymphocyte subset-based stratification in primary Sjögren's syndrome: implications for lymphoma risk and personalized treatment.Clinical rheumatology · 2025Article
- Management of Spontaneous Corneal Perforation in Undiagnosed Primary Sjögren's Syndrome.Cureus · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionPrimary Sjögren's is a multi-system autoimmune disease affecting patients' physical, mental, and emotional wellbeing. The epidemiology of Sjögren's is not well understood, and up-to-date epidemiological evidence is needed to improve knowledge and awareness of Sjögren's among patients and healthcare professionals, and to ascertain the global burden of disease. The objective of this research was to conduct a de novo systematic literature review (SLR) to identify and synthesise evidence on global epidemiology of primary Sjögren's.
methodsThis SLR was conducted in May 2021 by searching MEDLINE and Embase databases, relevant conference proceedings, websites of registries, and health technology assessment agencies and databases. Publications were systematically screened for English language articles reporting on the incidence, prevalence, age at symptom onset, and age at diagnosis for people with primary Sjögren's.
resultsOf 3510 records identified, 68 publications were included, representing 62 unique studies. Studies reported on age at symptom onset (16/62; 25.8%) and age at diagnosis (43/62; 69.4%) more frequently than incidence (7/62; 11.3%) and prevalence (9/62; 14.5%). Primary Sjögren's was found to have the highest incidence and prevalence in females and in older age groups (incidence: ≥65 years; prevalence: ≥75 years). Average age at onset and diagnosis of primary Sjögren's ranged between 34-57 years and 40-67 years, respectively.
conclusionsThis SLR identified a paucity of incidence and prevalence data for primary Sjögren's, highlighting a need for further epidemiological studies. The global Sjögren's community must work together to follow the defined classification criteria of primary Sjögren's and reporting guidelines for incidence and prevalence data to allow for meaningful epidemiological comparisons across studies, settings, and countries.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.